Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.

Blood type tied to prognosis in hepatocellular carcinoma

13 Jul 2017

Blood type is associated with prognosis in Chinese hepatocellular carcinoma (HCC) patients, a new study reveals. Those with non-O blood types particularly have poorer overall survival (OS).

Over a median follow-up of 36 (25 to 75) months, 392 of the 691 HCC patients who received hepatectomy died. The 3- and 5-year survival rates were 52.9 and 38.7 percent, respectively.

Blood group was significantly associated with OS (p=0.001). The median OS for blood type O was 55 (95 percent CI, 42.69 to 67.31) months, type A 39 (32.20 to 45.80) months, type B 34 (26.58 to 41.42) months and type AB 34 (24.09 to 43.91) months.

Because the 1-, 3- and 5-year OS values for the blood type O group (88.2, 58.8 and 47.3 percent, respectively) were significantly higher than the type A/B/AB groups, which had comparable OS values (p=0.226), the study cohort was divided into O vs non-O blood type groups.

The resulting median OS for the blood type O group was 55 (42.69 to 67.30) months vs 36 (31.18 to 40.81) months for the non-O blood type group. Patients with blood type O had significantly better survival than those with non-O blood types (1-year OS, 88.2 vs 83.4 percent; 3-year OS, 58.5 vs 49.1 percent; 5-year OS, 47.3 vs 30.5 percent; p<0.001 for all).

Multivariate Cox regression analysis revealed that blood types A (hazard ratio [HR], 1.416; 95 percent CI, 1.101 to 1.820; p=0.007), B (HR, 1.736; 1.333 to 2.262; p<0.001) and AB (HR, 1.739; 1.210 to 2.499; p=0.006) were significant poor prognostic factors for HCC following hepatectomy.

The non-O blood type group (HR, 1.485; 1.204 to 1.830; p<0.001) had significantly worse OS compared with the O blood type group.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.